Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02224794
Other study ID # 771-0014
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2014
Est. completion date June 2016

Study information

Verified date June 2021
Source Endologix
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The primary objectives of the LIFE Study are to demonstrate the clinical and cost benefits associated with using the Ovation® Abdominal Stent Graft Platform under the least invasive conditions defined in the Fast-Track EVAR protocol. The key elements of the Fast-Track EVAR protocol include: appropriate patient selection, bilateral percutaneous access, no general anesthesia, no ICU admission post procedure, and next day discharge.


Description:

The LIFE Study is a prospective, consecutively enrolling, non-randomized multi center post-market registry to evaluate the ultra low profile (14F) Ovation Abdominal Stent Graft Platform when using in the Percutaneous Endovascular Aneurysm Repair (P-EVAR) treatment of patients with AAA using a Fast-Track EVAR protocol. 250 study patients will be enrolled at up to 40 institutions. Follow-up period is one month.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient is = 18 years of age. - Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study). - Patient has signed an IRB approved informed consent form. - Patient is considered by the treating physician to be a candidate for elective open surgical repair of the AAA. - Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following: abdominal aortic aneurysm >5.0 cm in diameter, aneurysm has increased in size by 0.5 cm in last 6 months, or maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment. - Patient has suitable anatomy that allows use of the TriVascular Ovation® Abdominal Stent Graft Platform. - Patient has suitable femoral arteries at the percutaneous access site that allow use of the Perclose ProGlide Suture-Mediated Closure System via the pre-close technique. - Patient must be willing to comply with all required follow-up exams. Exclusion Criteria: - Patient has a need for emergent surgery. - Patient has a dissecting aneurysm. - Patient has an acutely ruptured aneurysm. - Patient has an acute vascular injury. - Patient has had a previous repair of the abdominal aortic aneurysm or the iliac artery. - Patient has a mycotic aneurysm or has an active systemic infection. - Patient has unstable angina. - Patient has unstable peripheral artery disease with critical limb ischemia. - Patient has congestive heart failure. - Patient has had a myocardial infarction and/or stroke within the past 3 months. - Patient requires use of techniques that would cover the renal arteries. - Patient requires planned adjunctive devices to complete the procedure. - Patient has a major surgical or interventional procedure planned during or within ±30 days of the AAA repair. - Patient has history of connective tissue disease. - Patient has history of bleeding disorders or refuses blood transfusions. - Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0mg/dl. - Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment. - Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol. - Patient is on home oxygen. - Patient is morbidly obese (BMI =40 kg/m2). - Patient was admitted from a skilled nursing facility. - Patient has a limited life expectancy of less than 1 year. - Patient has an inability to be discharged within 1 day of the procedure. - Patient is currently participating in an investigational device or drug clinical trial. - Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.

Study Design


Intervention

Device:
Ovation® Abdominal Stent Graft Platform


Locations

Country Name City State
United States St. Luke's Episcopal Hospital Houston Texas
United States Abrazo Arizona Heart Hospital Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
TriVascular, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major Adverse Events 30 days
Secondary Serious and non-serious adverse events, including vascular and major access site vascular complications 30 days
Secondary Assess technical success, defined as percent of procedures successfully completed with bilateral percutaneous access 30 days
Secondary Treatment success, defined as percent of subjects who successfully follow least invasive protocol through discharge 30 days
Secondary Blood loss, including if transfusion required 30 days
Secondary Percent of procedures completed without general anesthesia 30 days
Secondary Anesthesia time 30 days
Secondary Procedure time 30 days
Secondary Contrast volume 30 days
Secondary Fluoroscopy time 30 days
Secondary Time to hemostasis 30 days
Secondary Time to ambulation 30 days
Secondary Time to normal diet 30 days
Secondary Groin pain 30 days
Secondary Quality of Life 30 days
Secondary Percent of subjects discharged without ICU admission 30 days
Secondary Length of ICU stay, if required 30 days
Secondary Length of hospital stay 30 days
Secondary Percent of subjects discharged within only one midnight stay 30 days
Secondary Freedom from type I and III endoleaks 30 days
Secondary Freedom from AAA rupture 30 days
Secondary Freedom from conversion to open repair 30 days
Secondary Freedom from AAA related secondary interventions 30 days
Secondary Freedom from mortality 30 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04227054 - Abdominal Aortic Aneurysm Sac Healing and Prevention of Endoleaks N/A
Active, not recruiting NCT03687489 - Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System N/A
Active, not recruiting NCT03507413 - Metformin Therapy in Non-diabetic AAA Patients Phase 2/Phase 3
Not yet recruiting NCT05756283 - The PREHAAAB Trial: Multimodal Prehabilitation for Patients Awaiting Open Abdominal Aortic Aneurysm Repair N/A
Not yet recruiting NCT04089241 - Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair N/A
Active, not recruiting NCT02604303 - A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms
Completed NCT02229006 - Sodium Fluoride Imaging of Abdominal Aortic Aneurysms N/A
Terminated NCT01843335 - Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair N/A
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT01118520 - AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) Phase 2
Terminated NCT01425242 - Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension N/A
Completed NCT00746122 - Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair N/A
Completed NCT03952780 - Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)
Completed NCT00583414 - Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients N/A
Recruiting NCT05864560 - Ankura™ AAA, Cuff and AUI Stent Graft System Post-Market Clinical Follow-Up
Completed NCT01683084 - Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Phase 4
Active, not recruiting NCT03180996 - Global Fenestrated Anaconda Clinical sTudy
Completed NCT02493296 - The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study
Completed NCT03320408 - Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers
Completed NCT03837704 - Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking. N/A

External Links